Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health provider marketplace matching patients with therapists and psychiatrists accepting insurance; San Francisco-based;
Path Mental Health is a San Francisco-based mental health platform that matches patients with therapists, psychologists, and psychiatrists who accept insurance, addressing the core access barrier in mental healthcare. Path handles the insurance verification, paperwork, and administrative overhead of connecting patients to in-network mental health providers, offering both individual therapy and medication management services. The platform targets the large population of individuals who want to use their health insurance for mental health care but struggle to find providers who are accepting new patients and take their specific insurance plan. Path works with major commercial insurers and provides access to licensed providers via telehealth and in-person sessions depending on location. Founded in 2019, Path raised over $120M from investors including Andreessen Horowitz and Foresite Capital. The company competes with Alma, Headway, and Grow Therapy in the therapist network and patient matching market.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.